Moderna shares rose after the biotechnology company increased its 2026 revenue projections, citing momentum from its latest vaccine offerings.
Coverage spectrum
Read at your length
Moderna shares rose after the biotechnology company increased its 2026 revenue projections, citing momentum from its latest vaccine offerings.
The company lifted its sales outlook for the year, saying it expects revenue to grow as much as 25% in 2026. The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
MarketWatch reported the story as "Moderna raises its revenue outlook - but all eyes are on what happens next with its cancer vaccine."
2 sources have covered this story, including MarketWatch and CNBC. The earliest reporting in the cluster landed about 6 hours ago.
How each side is reporting it
How the left is reporting it
How the wires + center are reporting it
How the right is reporting it
Where sources agree
No shared facts cached yet.
Where they diverge
No contradictions cached yet.
How it spread
Claim ledger
[01] VerifiedCore event reported by 2 independent outlets across the spectrum.
[02] DisputedKey facts present in mainstream desks; corroboration thin from wires.